Revised: October 2015
Minor amendment to section 6.1
* Based on Ph. Eur. serology test)
≥ 3.25 IU/ml of Rabies glycoprotein inducing ≥ 1.4 log10 IU/ml*
Adjuvant: Aluminium Hydroxide
For full list of excipients, see section 6.1
Vanguard Rabies vaccine is a sterile opaque suspension for subcutaneous injection, with an off-white precipitate which readily resuspends on shaking.
Indications for use, specifying the target species
For the active immunisation of cats and dogs to prevent infection and mortality due to rabies.
An antibody response normally develops within 7-14 days after vaccination. Vaccinated animals should not be exposed to the risk of rabies infection for 14 days. The specific immune response confers immunity for up to 3 years.
Do not use in unhealthy animals.
Do not use in pregnant animals.
Special warnings for each target species
Do not vaccinate animals for at least one month following the administration of immuno-suppressive drugs.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
No special precautions apply.
As with all vaccines, occasional hypersensitivity may occur. In such cases, appropriate treatment, such as adrenalin, should be administered without delay.
In dogs, treatment with the vaccine produces oedematous swelling of up to 3.8 cm maximum diameter (5.4 cm3max. volume) at the site of injection. This swelling resolves with time and disappears by 21 days after treatment.
Treatment of cats with the vaccine produces a swelling of about 2-3 cm in diameter and raised by about 0.1 cm. at the site of injection. This swelling resolves with time and disappears by 24 hours after treatment. In some animals a fibrous nodule of 3 - 8 mm in diameter may develop at the site of injection 14 to 21 days after treatment. These nodules should resolve uneventfully over a period of 14 to 35days.
Do not use in pregnant animals
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Amounts to be administered and administration route
Cats and dogs: 1 mL by subcutaneous injection.
1 mL dose.
Cats and dogs may be vaccinated from 3 months of age and should be re-vaccinated every three years
Cats: Treatment with a double dose of vaccine produces no systemic reaction. At the site of injection a swelling of about 2 - 3 cm in diameter and raised by about 0.2 cm occurs soon after treatment. This swelling disappears by 3 days after treatment. About 7 -21 days after treatment fibrous nodules may develop at the site of injection. These nodules should resolve uneventfully after a maximum of 35daysfollowing their appearance.
Dogs: Treatment with a double dose of vaccine produces no systemic reaction. At the site of injection oedematous swelling of up to 4.5 cm maximum diameter (9 cm3max. volume) occurs soon after treatment. This swelling disappears by 28 days after treatment.
To stimulate active immunity against rabies.
List of excipients
Do not mix with any other vaccine/immunological product.
Shelf life of the veterinary medicinal product as package for sale: 3 years
Shelf life after first opening the immediate packaging: use immediately
Store between +2° - +8°C.
Protect from light.
Do not freeze.
Nature and composition of immediate packaging
Single dose presentation (1mL) in a glass vial with bromobutyl rubber stopper and aluminium crimp seal. Printed cartons of 1 x 1 mL vial and 10 x 1 mL vials.
Not all pack sizes may be marketed.
MARKETING AUTHORISATION HOLDER
Zoetis UK Limited
5th Floor, 6 St. Andrew Street
MARKETING AUTHORISATION NUMBER
DATE OF FIRST AUTHORISATION
Date:23 May 2000
DATE OF REVISION OF THE TEXT
Date: October 2015
In any animal population, there may be a number of individuals which fail to respond fully to vaccination. Successful vaccination depends upon the correct storage and administration of the vaccine together with the animal’s ability to respond. This can be influenced by such factors as genetic constitution, intercurrent infection, age, the presence of maternally derived antibodies, nutritional status, concurrent drug therapy and stress.
Pet Travel Scheme (PETS)
Animals intended for vaccination under the Pet Travel Scheme (PETS) must be identified by a permanently numbered microchip. This microchip number must be recorded on the record of dog and cat vaccination at the time of rabies vaccination.
Approved: 02 September 2015
Page 8 of 8